Cladribine

Generic Name: Cladribine

Brand Names: Litak, Mavenclad

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂ClN_₅O_₃

CAS Number: 4291-63-8

Unique Ingredient Identifier: 47M74X9YT5

Background: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

Indication: For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Clinical Trials

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Chidamide
Drug: Cladribine

First Posted Date: 2022-04-15

Last Posted Date: 2022-04-29

Lead Sponsor: Ge Zheng

Target Recruit Count: 31

Registration Number: NCT05330364

Locations: 🇨🇳
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

Phase 2

Recruiting

Conditions: Pediatric AML
Leukemia, Monocytic, Acute

Interventions: Drug: Cladribine
Drug: G-CSF
Drug: Cytarabine
Drug: Idarubicin
Drug: Mitoxantrone
Drug: Sorafenib

First Posted Date: 2022-04-06

Last Posted Date: 2023-07-27

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 43

Registration Number: NCT05313958

Locations: 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China

and more 6 locations

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Not Applicable

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Azacitidine
Drug: Cladribine
Drug: Cytarabine
Drug: Idarubicin

First Posted Date: 2021-09-22

Last Posted Date: 2022-04-26

Lead Sponsor: LanZhou University

Target Recruit Count: 30

Registration Number: NCT05053425

Locations: 🇨🇳
Long Zhao, Lanzhou, Gansu, China

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine

First Posted Date: 2021-06-22

Last Posted Date: 2024-05-17

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 256

Registration Number: NCT04934800

Locations: 🇬🇷
Papageorgiou General Hospital Thessaloniki, Thessaloniki, Greece
🇬🇷
University General Hospital of Patra, Patras, Greece
🇬🇷
General Hospital of Patra "Agios Andreas", Patra, Greece

and more 58 locations

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Phase 3

Recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: BEAC
Drug: Cladribine combined with BEAC

First Posted Date: 2021-05-11

Last Posted Date: 2021-05-11

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 266

Registration Number: NCT04880746

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia Myelodysplastic Syndromes

Interventions: Drug: Cladribine

First Posted Date: 2021-04-27

Last Posted Date: 2025-04-24

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 40

Registration Number: NCT04861207

Locations: 🇵🇱
Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach, Gliwice, Poland

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Secondary Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Uproleselan

First Posted Date: 2021-04-19

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT04848974

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Phase 1

Recruiting

Conditions: Acute Biphenotypic Leukemia
Mixed Phenotype Acute Leukemia
Relapsed Acute Myeloid Leukemia
Relapsed Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia
Relapsed Acute Biphenotypic Leukemia
Relapsed Myeloid Neoplasm
Refractory Acute Biphenotypic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Refractory Myeloid Neoplasm

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Mitoxantrone
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Venetoclax
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2021-03-15

Last Posted Date: 2025-05-04

Lead Sponsor: University of Washington

Target Recruit Count: 62

Registration Number: NCT04797767

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Mavenclad®

First Posted Date: 2021-03-05

Last Posted Date: 2025-01-22

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 219

Registration Number: NCT04783935

Locations: 🇮🇹
Dipartimento di internistica clinica e sperimentale "Flaviano Magrassi"Università degli studi della Campania "Luigi Vanvitelli", Napoli, Italy
🇦🇺
John Hunter Hospital, New Lambton, Australia
🇦🇺
Liverpool Hospital, Liverpool, Australia

and more 43 locations

Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Mavenclad®

First Posted Date: 2021-03-01

Last Posted Date: 2024-05-28

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 280

Registration Number: NCT04776213

Locations: 🇫🇷
CHRU de Lille Hôpital Roger Salengro, Lille, France
🇫🇷
CHU Hôpital Nord Laennec, Nantes Cedex 01, France
🇮🇹
Instituto Nazionale Neurologico "Carlo Besta", Milano, Italy

and more 57 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy